Who are Cullinan Therapeutics's investors?

Cullinan Therapeutics's investors include Foresite Capital, Nextech Invest, Biotechnology Value Fund, OrbiMed.

Cullinan Therapeutics

NASDAQ: CGEM

Incorporated in Delaware · 4 known investors

Find your way into Cullinan Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Cullinan Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.

Biotech Healthtech Medical Devices

Founders & leadership

Mary Kay Fenton Chief Financial OfficerMary Kay Fenton is Chief Financial Officer at Cullinan Therapeutics, a clinical-stage biotech company developing therapeutics for autoimmune diseases and cancer. She brings experience in capital formation across venture, mezzanine, and public markets, as well as expertise in strategic transactions, financial reporting, and Sarbanes-Oxley compliance, with prior roles at Big Four firms and an MBA and CPA.

Jeffrey JonesChief Medical Officer

Jennifer Michaelson Chief Scientific OfficerJennifer Michaelson is Chief Scientific Officer at Cullinan Therapeutics, a clinical-stage biotech company developing therapeutics for autoimmune diseases and cancer. She has over 20 years of experience in drug discovery and development across oncology, immunology, and immuno-oncology, including portfolio management through IND applications and early clinical development, and has contributed to multiple biotech company fundraising rounds and published over 50 peer-reviewed papers.

Corinne Savill Chief Business OfficerShe holds a PhD in Immunology from the University of London and has worked in business development roles across the biotech and pharmaceutical industries, with experience in oncology and international business development.

Jacquelyn SumerChief Legal Officer, Corporate Secretary, Chief Compliance Officer

Nadim Ahmed President and CEONadim Ahmed is President and CEO of Cullinan Therapeutics, a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer through immune modulation.

Investors · 4

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: funding news · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: the VCSheet dataset · Not right? Tell us

Valuation · disclosed

Disclosed events

$876.1Mvaluation at IPOJan 2021 · $21.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 2

Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

C4 TherapeuticsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.

Companies working in the same space as Cullinan Therapeutics.

Acquisitions · 1

Early investors' stakes continue via these deals

PDI Therapeutics

Developed a first-in-class monoclonal antibody for multiple cancers; acquired by Cullinan Therapeutics in 2022.

Frequently asked questions

What does Cullinan Therapeutics do?: Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.
Who are Cullinan Therapeutics's investors?: Cullinan Therapeutics's investors include Foresite Capital, Nextech Invest, Biotechnology Value Fund, OrbiMed.